The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.

•In R/M NPC treated with PD-1 inhibitors, the ORR was 27% and the DCR was 63%.•The 1-year PFS rates was 25% in the PD-1 inhibitors treatment.•The 1-year OS rate was 61% when R/M NPC was treated with anti-PD-1 agents.